InBody's stock has surged to its upper limit following a significant increase in its first-quarter earnings compared to last year.
According to the Korea Exchange, as of 10:20 a.m. on May 8, InBody's shares rose by 8,850 won (29.85%) to 38,500 won, reaching the maximum allowable price increase.
The company reported that its consolidated revenue for the first quarter of this year was 68.445 billion won, a 23.1% increase from the same period last year. Operating profit soared by 86% to 13.025 billion won, while net profit jumped 138.1% to 16.298 billion won.
Kim Chung-hyun, a researcher at Mirae Asset Securities, noted, "Revenue exceeded market expectations, marking the ninth consecutive quarter of record performance," adding that operating profit also surpassed forecasts.
He further stated, "As the obesity treatment market grows in the U.S. and Europe, obesity clinics and pharmaceutical companies researching obesity treatments are emerging as new demand sources. The obesity treatment market will continue to provide growth momentum."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.